Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · IEX Real-Time Price · USD
22.57
-0.48 (-2.08%)
At close: Jul 2, 2024, 4:00 PM
22.68
+0.11 (0.49%)
After-hours: Jul 2, 2024, 7:13 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 507 employees as of December 31, 2022. The number of employees increased by 166 or 48.68% compared to the previous year.
Employees
507
Change (1Y)
166
Growth (1Y)
48.68%
Revenue / Employee
$711,856
Profits / Employee
-$265,751
Market Cap
1.86B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 507 | 166 | 48.68% |
Dec 31, 2021 | 341 | 160 | 88.40% |
Dec 31, 2020 | 181 | 63 | 53.39% |
Dec 31, 2019 | 118 | 31 | 35.63% |
Dec 31, 2018 | 87 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
BrightSpring Health Services | 35,000 |
Addus HomeCare | 34,846 |
AMN Healthcare Services | 18,223 |
LifeStance Health Group | 9,325 |
Warby Parker | 3,491 |
Premier | 2,800 |
Amphastar Pharmaceuticals | 1,761 |
Rocket Pharmaceuticals | 268 |
BEAM News
- 6 days ago - Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 19 days ago - Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 4 months ago - Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences - GlobeNewsWire